微创、高效、直达大脑！我国科学家开辟脑卒中病灶给药新路径

Core Viewpoint - The research teams from Tsinghua University and Capital Medical University have developed a novel method to bypass the blood-brain barrier using nanoparticles to deliver drugs directly to stroke lesions, potentially overcoming a significant challenge in neurological disease treatment [1][3]. Group 1: Research Findings - The study reveals that the bone marrow within the skull is not a static structure but is connected to the meninges through microchannels, allowing immune cells to bypass the blood-brain barrier and enter the brain [3]. - The research team utilized a minimally invasive injection method to deliver albumin nanoparticles into the skull bone marrow, which were efficiently taken up by immune cells, forming "skull immune cell micro-nanobots" for targeted drug delivery [3][4]. - The nanoparticles demonstrated low systemic exposure, with minimal entry into peripheral blood and major organs, ensuring good biocompatibility and safety [3][4]. Group 2: Clinical Implications - In mouse models of acute ischemic stroke, the new delivery method significantly reduced infarct volume and edema, improved neurological function, and showed long-term benefits in reducing brain atrophy and enhancing survival rates [4]. - An exploratory clinical study involving 20 patients with malignant cerebral artery occlusion indicated that the procedure was well-tolerated, with no severe adverse events reported, and showed positive trends in neurological recovery [4][5]. Group 3: Future Prospects - The research suggests that this delivery pathway could extend beyond drug delivery, potentially integrating with brain-machine interface technologies to facilitate multi-directional exchanges of materials, energy, and information between the brain and artificial systems [5].